- The Washington Times - Monday, March 22, 2004

Patients on some popular antidepressants should be monitored closely for warning signs of suicide, the government said yesterday in asking the makers of 10 drugs to add the caution to their labels.

Although the Food and Drug Administration’s investigation into the suicide connection initially focused on children given the drugs, its warning is aimed at both adult and pediatric use of the pills to alleviate depression.

It isn’t clear whether the drugs actually lead to suicide, the FDA stressed, pointing out that depression itself can lead to suicide.

But until that question is settled, advisers to the FDA called last month for stronger warnings to doctors and parents that the antidepressants might cause agitation, anxiety and hostility in a subset of patients who might be unusually prone to rare side effects.

The drugs of concern are all newer-generation antidepressants: Prozac, Paxil, Zoloft, Effexor, Celexa, Remeron, Lexapro, Luvox, Serzone and Wellbutrin. Most are known to affect the brain chemical serotonin.

On Monday, the FDA followed its advisers’ recommendation and issued a public-health advisory putting doctors, patients, families and other caregivers on notice to be particularly vigilant for signs of worsening depression or suicidal thoughts at the beginning of antidepressant therapy or whenever the dose is changed.

British health authorities sounded the alarm last year, saying long-suppressed research suggests that certain antidepressants sometimes might increase the risk of suicidal behavior in children and teenagers. Because only one drug, Prozac, has been proven to alleviate pediatric depression, Britain declared others — drugs called selective serotonin reuptake inhibitors (SSRIs) and their close relatives — unsuitable for depressed youth.

The FDA issued a caution on pediatric use last year, but Monday’s action — especially the addition of the warning to drug labels — goes significantly further.

Dozens of anguished parents pleaded with FDA in a meeting last month to add such warnings, citing cases of preteens and teenagers who hanged themselves or slashed their wrists shortly after starting the antidepressants. Several parents described children who had become extremely agitated or anxious shortly after starting the antidepressants and seemingly sudden impulses that turned deadly.

Among 25 studies of the suspect medications involving 4,000 children and teens, there were no completed suicides. But 109 patients experienced one or more possibly suicide-related behaviors or attempts, the FDA says.

The studies varied dramatically in what was considered suicidal behavior, making a clear link difficult, FDA scientists have contended. For example, among 19 patients classified as cutting themselves, almost all were superficial, with little bleeding.

Worse, the youths most likely to commit suicide weren’t allowed into those studies, so existing data likely won’t settle the issue, the FDA’s scientific advisers have warned.

Depression occurs in up to 10 percent of youth, and 1,883 10- to 19-year-olds killed themselves in 2001. About 1.8 million teenagers attempted suicide that year, a quarter of them requiring medical attention, according to Columbia University scientists who are helping with the FDA’s probe.

In 2002, almost 11 million prescriptions were dispensed to patients younger than 18 for SSRIs and other newer antidepressants to treat depression and a host of other conditions, the FDA said.

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide